Orchid Pharma Limited

NSEI:ORCHPHARMA Stock Report

Market Cap: ₹75.1b

Orchid Pharma Future Growth

Future criteria checks 5/6

Orchid Pharma is forecast to grow earnings and revenue by 43.7% and 31.8% per annum respectively. EPS is expected to grow by 41.8% per annum. Return on equity is forecast to be 17.7% in 3 years.

Key information

43.7%

Earnings growth rate

41.8%

EPS growth rate

Pharmaceuticals earnings growth18.1%
Revenue growth rate31.8%
Future return on equity17.7%
Analyst coverage

Low

Last updated14 Aug 2024

Recent future growth updates

No updates

Recent updates

Earnings Tell The Story For Orchid Pharma Limited (NSE:ORCHPHARMA) As Its Stock Soars 26%

Jul 29
Earnings Tell The Story For Orchid Pharma Limited (NSE:ORCHPHARMA) As Its Stock Soars 26%

We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease

Jun 12
We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease

Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

May 08
Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce

Feb 28
Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce

Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Feb 06
Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump

Dec 18
Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump

Earnings and Revenue Growth Forecasts

NSEI:ORCHPHARMA - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202722,7314,7281,836N/A1
3/31/202615,0242,164-1,935N/A3
3/31/202510,4221,436-1,805N/A2
6/30/20248,8091,121N/AN/AN/A
3/31/20248,1949226121,260N/A
12/31/20238,1221,246N/AN/AN/A
9/30/20237,5131,0275461,043N/A
6/30/20237,178775N/AN/AN/A
3/31/20236,659531-666183N/A
12/31/20226,341-175N/AN/AN/A
9/30/20226,357-35675782N/A
6/30/20225,982-471N/AN/AN/A
3/31/20225,596-604781925N/A
12/31/20215,010-592N/AN/AN/A
9/30/20214,424-934364393N/A
6/30/20214,232-1,009N/AN/AN/A
3/31/20214,501-952230236N/A
12/31/20204,420-1,307N/AN/AN/A
9/30/20204,687-1,136N/AN/AN/A
6/30/20204,918-1,153N/AN/AN/A
3/31/20204,838-697766808N/A
3/31/20196,00069454120N/A
3/31/20186,830-3,528N/A92N/A
3/31/20177,965-4,954N/A4,010N/A
3/31/20168,734-2,791N/A2,122N/A
3/31/201511,644-1,311N/A-2,460N/A
9/30/201312,985-3,720N/A1,121N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ORCHPHARMA's forecast earnings growth (43.7% per year) is above the savings rate (6.7%).

Earnings vs Market: ORCHPHARMA's earnings (43.7% per year) are forecast to grow faster than the Indian market (17% per year).

High Growth Earnings: ORCHPHARMA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ORCHPHARMA's revenue (31.8% per year) is forecast to grow faster than the Indian market (10.1% per year).

High Growth Revenue: ORCHPHARMA's revenue (31.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ORCHPHARMA's Return on Equity is forecast to be low in 3 years time (17.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y